Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Myeloproliferative Disorders and Leukemia
NCT00255346Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2005
- Primary completion
- Mar 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myelofibrosis (MF), hypereosinophilic syndrome (HES), polycythemia vera (PV), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2005; status: completed.
02
Drugs
dasatinib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myelofibrosis (MF)hypereosinophilic syndrome (HES)polycythemia vera (PV)
Beyond the preview
Go deeper on NCT00255346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00255346.